by François Briand | Oct 30, 2024 | 2024
Physiogenex now delivers its novel rat model of IgA nephropathy (IgAN) to rapidly evaluate the efficacy of drugs targeting IgAN, in only 8 days! The model has been presented at the ASN Kidney Week 2024 on October 26th, 2024 in San Diego: Click here to view the poster...
by François Briand | Mar 3, 2024 | 2024
iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models – check the poster content here If you are interested to evaluate your novel therapies with Physiogenex, feel free to contact us to discuss your next...
by François Briand | Jan 30, 2024 | 2024
HepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4 mouse model of liver fibrosis. Review the manuscript here. If you also wish to demonstrate the efficacy of your therapies in Physiogenex models, feel free to...